Quantitative T2 mapping of recurrent glioblastoma under bevacizumab improves monitoring for non-enhancing tumor progression and predicts overall survival

BACKGROUND: Anti-angiogenic treatment in recurrent glioblastoma patients suppresses contrast enhancement and reduces vasogenic edema while non-enhancing tumor progression is common. Thus, the importance of T2-weighted imaging is increasing. We therefore quantified T2 relaxation times, which are the...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Hattingen, Elke, Jurcoane, Alina, Daneshvar, Keivan, Pilatus, Ulrich, Mittelbronn, Michel, Steinbach, Joachim P., Bähr, Oliver
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Oxford University Press 2013
Onderwerpen:
Clinical Investigations
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3779046/
https://ncbi.nlm.nih.gov/pubmed/23925453
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/not105
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items